Other, there are also lots of TMEM16A inhibitors which are not still fully investigated the anti-tumor effect; MONNA [121], AACT [122], digallic acid [123], evodiamine, rutecarpine [124], purpactin A [125], nimodipine [126], and more. This evidence concerns the gene ANO1 and neoplasm.